#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
What Obesity Drug Cost Models Show
A systematic review of economic evaluations finds anti-obesity medicine cost-effectiveness varies by setting, price, assumptions, and comparator.
Why a peptide list is not a treatment plan
A community peptide list can show what is being discussed, but it cannot establish safety, evidence or suitability for an individual.
GLP-1 Use After Bariatric Surgery
A retrospective cohort found no statistically significant weight-loss difference after bariatric surgery when GLP-1 medicines were started within a year.
Are healthcare systems ready for GLP-1s?
GLP-1 readiness requires continuity, transparent access rules and realistic expectations, not only an effective prescription.
HISTORI Semaglutide Record: What We Know
A PubMed record describes a semaglutide trial in schizophrenia, prediabetes, and obesity, but currently supplies no abstract or outcome data.
MASH combination therapy: review insights
A 2026 review explains why MASH combination therapy is being explored, while leaving major questions unresolved.
MASH eligibility tests: study findings
A multicentre cohort found that proposed non-invasive MASH eligibility criteria classified many patients differently.
Retatrutide and gut-health claims
A podcast discussion can raise useful questions, but phase 2 retatrutide evidence does not make it an approved general tool for gut health.
STEP UP semaglutide muscle findings
A small STEP UP MRI subgroup found lower thigh fat infiltration and lower measured muscle volume, with sit-to-stand repetitions preserved.
What 49 Online GLP-1 Prescribers Required
A secret-shopper study found rapid access to GLP-1 prescriptions across 49 US websites, often without direct clinician-patient communication.
Semaglutide Plus Niacin for Lung Fibrosis
A rat study paired semaglutide with niacin against lung scarring, targeting the NAD+/SIRT1-FOXO3a-Nrf2 pathway. Here is what it does and does not show.
Tirzepatide, GLP-1 Drugs, and Gum Disease
A large propensity-matched study links tirzepatide to lower periodontal disease risk than other GLP-1 drugs in type 2 diabetes.